9SC

7-[4-[4-[2,3-bis(chloranyl)phenyl]piperazin-1-yl]butoxy]-3,4-dihydro-1H-quinolin-2-one


Toggle HydrogenToggle Labels

Chemical Component Summary

Name7-[4-[4-[2,3-bis(chloranyl)phenyl]piperazin-1-yl]butoxy]-3,4-dihydro-1H-quinolin-2-one
SynonymsAripiprazole
Identifiers7-[4-[4-[2,3-bis(chloranyl)phenyl]piperazin-1-yl]butoxy]-3,4-dihydro-1~{H}-quinolin-2-one
FormulaC23 H27 Cl2 N3 O2
Molecular Weight448.385
TypeNON-POLYMER
Isomeric SMILESc1cc(c(c(c1)Cl)Cl)N2CCN(CC2)CCCCOc3ccc4c(c3)NC(=O)CC4
InChIInChI=1S/C23H27Cl2N3O2/c24-19-4-3-5-21(23(19)25)28-13-11-27(12-14-28)10-1-2-15-30-18-8-6-17-7-9-22(29)26-20(17)16-18/h3-6,8,16H,1-2,7,9-15H2,(H,26,29)
InChIKeyCEUORZQYGODEFX-UHFFFAOYSA-N

Chemical Details

Formal Charge0
Atom Count57
Chiral Atom Count0
Bond Count60
Aromatic Bond Count12

Drug Info: DrugBank

DrugBank IDDB01238 
NameAripiprazole
Groups
  • approved
  • investigational
DescriptionAripiprazole is an atypical antipsychotic orally indicated for the treatment of schizophrenia, bipolar I, major depressive disorder, irritability associated with autism, and Tourette's.[L45859] It is also indicated as an injection for agitation associated with schizophrenia or bipolar mania.[L45859] Aripiprazole exerts its effects through agonism of dopaminergic and 5-HT1A receptors and antagonism of alpha-adrenergic and 5-HT2A receptors.[L45859,A4393] Aripiprazole was given FDA approval on November 15, 2002.[L6136]
Synonyms
  • Aripiprazole
  • Aripiprazolum
  • Aripiprazol
Brand Names
  • Auro-aripiprazole
  • Abilify Asimtufii
  • Teva-aripiprazole
  • Aripiprazole Accord
  • Abilify Maintena
IndicationAripiprazole is indicated for the treatment of acute manic and mixed episodes associated with bipolar I disorder, irritability associated with autism spectrum disorder, schizophrenia, and Tourette's disorder.[L45859] It is also used as an adjunctive treatment of major depressive disorder.[L45859 An injectable formulation of aripiprazole is indicated for agitation associated with schizophrenia or bipolar mania.[L45859] Finally, an extended-release, bimonthly injection formulation of aripiprazole is indicated for the treatment of adult schizophrenia and maintenance therapy for adult bipolar I disorder.[L46203]
Categories
  • Adrenergic alpha-1 Receptor Antagonists
  • Adrenergic alpha-Antagonists
  • Adrenergic Antagonists
  • Agents producing tachycardia
  • Agents that produce hypertension
ATC-CodeN05AX12
CAS number129722-12-9

Drug Targets

NameTarget SequencePharmacological ActionActions
Dopamine D2 receptorMDPLNLSWYDDDLERQNWSRPFNGSDGKADRPHYNYYATLLTLLIAVIVF...unknownantagonist,partial agonist
5-hydroxytryptamine receptor 2AMDILCEENTSLSSTTNSLMQLNDDTRLYSNDFNSGEANTSDAFNWTVDSE...unknownantagonist
5-hydroxytryptamine receptor 1AMDVLSPGQGNNTTSPPAPFETGGNTTGISDVTVSYQVITSLLLGTLIFCA...unknownpartial agonist
Alpha-1A adrenergic receptorMVFLSGNASDSSNCTQPPAPVNISKAILLGVILGGLILFGVLGNILVILS...unknownantagonist
Alpha-1B adrenergic receptorMNPDLDTGHNTSAPAHWGELKNANFTGPNQTSSNSTLPQLDITRAISVGL...unknownantagonist
View More
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682

Related Resource References

Resource NameReference
Pharos CHEMBL1112
PubChem 60795
ChEMBL CHEMBL1112
ChEBI CHEBI:31236
CCDC/CSD MELFIT09, MELFIT07, MELFIT14, MELFIT16, MELFIT11, KAHROD, MELFIT15, MELFIT17, MELFIT18, KAJFEJ, MELFIT20, MELFIT10, MELFIT13, MELFIT08, MELFIT12, MELFIT05, MELFIT06, MOXDAF01, KAHRIX, MELFIT, MELFOZ, MELFIT01, MELFIT04, MELFUF01, MELFOZ01, MELFIT03, OSAZOA, OSAZUG
COD 7223730, 7215035, 7223732